Cerenome is trading 5.17% up at $2.85, with no company-specific announcement identified for September 2, 2026.
- CNBC reports no recent news for the security.
- The latest quarterly update showed a revenue miss and wider-than-expected loss, making it an unlikely catalyst for today’s gain.
- The broader healthcare sector is stronger, supported by Medtronic earnings and positive GSK vaccine news, suggesting sector-driven buying.